SCHEMBL427556

SCHEMBL427556

CN(C(=O)n1cnc(-c2ccc(C(N)=O)cc2)c1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
MAP4K4 O95819 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
FYN P06241 1/20 0.42
MKNK1 Q9BUB5 3/20 0.42
MKNK2 Q9HBH9 2/20 0.42
PHGDH O43175 1/20 0.42
CHEK2 O96017 2/20 0.41
PLAU P00749 1/20 0.40
ACHE P22303 2/20 0.39
LIPE Q05469 2/20 0.39
CAMKK2 Q96RR4 2/20 0.39
MAPK8 P45983 2/20 0.38
PIK3CG P48736 1/20 0.38
GSK3B P49841 1/20 0.38
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427476 0.88 FAAH (0.57) FAAHSMN1; SMN2ACHELIPEKDM4E
SCHEMBL425371 0.88 FAAH (0.60) FAAHSMN1; SMN2ACHELIPEKDM4E
SCHEMBL426994 0.87 FAAH (0.51) FAAHSMN1; SMN2PHGDHACHELIPE
SCHEMBL426698 0.86 FAAH (0.52) FAAHSMN1; SMN2FYNMKNK1MKNK2
SCHEMBL425550 0.85 FAAH (0.51) FAAHSMN1; SMN2KDM4ELMNATP53
SCHEMBL425400 0.85 FAAH (0.54) FAAHMAP4K4SMN1; SMN2ACHELIPE
SCHEMBL425535 0.82 FAAH (0.49) FAAHSMN1; SMN2ACHELIPEKDM4E
SCHEMBL426694 0.82 ACHE (0.49) FAAHSMN1; SMN2PHGDHACHELIPE
SCHEMBL425420 0.80 FAAH (0.52) FAAHSMN1; SMN2FYNKDM4E
SCHEMBL426080 0.80 FAAH (0.52) FAAHSMN1; SMN2FYNABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885MAP4K4 3117/4885SMN1; SMN2 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.